We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00238849
Recruitment Status : Unknown
Verified October 2005 by Integrated Community Oncology Network.
Recruitment status was:  Not yet recruiting
First Posted : October 14, 2005
Last Update Posted : October 14, 2005
Information provided by:

October 12, 2005
October 14, 2005
October 14, 2005
Not Provided
Not Provided
Same as current
No Changes Posted
  • Time to progression
  • Duration of response
  • Survival
  • Toxicity profile
Same as current
Not Provided
Not Provided
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Previously Treated Metastatic Non-Small Cell Lung Cancer
Drug: Oxaliplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided

Inclusion Criteria:

  • Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.
  • Measurable disease
  • Good performance status (ECOG 0,1 or 2)

Exclusion Criteria:

  • Previously treated with Oxaliplatin or Navelbine
  • Symptomatic CNS metastases
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Integrated Community Oncology Network
Principal Investigator: Thomas A Marsland, MD Integrated Community Oncology Network
Integrated Community Oncology Network
October 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP